Inappropriate Shocks From Implantable Cardioverter-Defibrillators

Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death by recognising dangerous ventricular tachycardia or ventricular fibrillation and delivering antitachycardia pacing or a high-energy shock. The same sensing and detection systems can sometimes classify a rapid but non-lethal rhythm as ventricular arrhythmia. These events, known as inappropriate shocks, are clinically important because they cause pain, anxiety, avoidable emergency presentations and, in some cases, myocardial injury.

The problem is relevant across ICDs used for primary and secondary prevention, including transvenous systems and subcutaneous ICDs. Atrial fibrillation with a rapid ventricular response is a familiar trigger, but sinus tachycardia, atrial flutter, supraventricular tachycardia, lead malfunction, T-wave oversensing and electromagnetic interference can produce similar episodes. Careful interrogation of stored electrograms is essential before changing therapy.

For Australian patients, management often spans a metropolitan electrophysiology service and local cardiology or general practice. Someone living in regional New South Wales, Queensland or Western Australia may rely heavily on remote monitoring between visits to Sydney, Brisbane, Perth or another tertiary centre. Access, Medicare arrangements, private insurance, device-vendor support and travel distance all influence how quickly a suspected ICD problem is assessed.

Why inappropriate shocks occur

The most common clinical cause is a supraventricular tachyarrhythmia that enters the ICD detection zone. Atrial fibrillation, atrial flutter, focal atrial tachycardia and atrioventricular nodal re-entry tachycardia may produce ventricular rates high enough to satisfy programmed criteria for ventricular tachycardia. Sinus tachycardia during exercise, fever, pain or severe emotional stress can have the same effect, particularly when the detection threshold is set too low.

Device-related sensing errors form a second major group. A fractured conductor, insulation defect, loose set screw or poor lead contact may create non-physiological signals. T-wave oversensing occurs when repolarisation is interpreted as an additional ventricular event, effectively doubling the measured rate. Myopotential sensing, pocket movement and electrical interference are less common but should be considered when stored electrograms do not resemble a true tachyarrhythmia.

The clinical context matters. A patient with atrial fibrillation may benefit from a rhythm-control strategy, while a patient with a lead problem may need urgent revision or extraction assessment. The journal’s discussion of monitoring AF recurrence is relevant when recurrent atrial arrhythmia is suspected after ablation and device records show a changing burden of AF.

Interpreting the stored electrograms

An ICD interrogation should establish what the device detected, which therapy was delivered and whether the episode was appropriate. Clinicians review atrial and ventricular electrograms, marker channels, lead impedance, sensing amplitudes, pacing thresholds, charge time and episode history. The timing of atrial and ventricular activation can distinguish a rapid atrial rhythm with variable conduction from ventricular tachycardia, although interpretation may be difficult when atrial sensing is unreliable.

A sudden change in lead impedance, repeated short episodes, a high-voltage lead alert or noise seen on near-field and far-field recordings should raise concern for lead malfunction. In contrast, regular ventricular intervals with a stable morphology may support sinus tachycardia or an organised supraventricular rhythm. The absence of an alert does not exclude an intermittent fault, so the patient’s symptoms and a review of earlier transmissions remain important.

Patients should receive clear safety advice after a shock. A single shock without ongoing symptoms warrants prompt contact with the treating service. Repeated shocks, syncope, chest pain, severe breathlessness or a shock occurring during sustained palpitations require urgent emergency assessment. Australian emergency departments should be given the device identification details when available, as these help the cardiology and device teams obtain a rapid interrogation.

Programming that lowers avoidable therapy

Programming can reduce inappropriate therapy without compromising protection from ventricular arrhythmia. Higher detection-rate cut-offs and longer detection intervals allow brief, self-terminating episodes to end before a shock is delivered. In selected patients, trials such as MADIT-RIT and ADVANCE III support strategies that combine higher-rate therapy zones or delayed detection with appropriate clinical oversight.

Modern ICDs also use supraventricular tachycardia discriminators. These may compare ventricular and atrial rates, assess onset and stability, examine morphology against a template, and evaluate the relationship between atrial and ventricular events. Their performance depends on the rhythm, device type, lead configuration and programmed limits. Discriminators should be tailored to the patient rather than activated without checking whether they remain safe during the likely ventricular arrhythmias.

Antitachycardia pacing can terminate many monomorphic ventricular tachycardias painlessly and may reduce the number of shocks. Programming a monitor-only zone can provide useful diagnostic information for slower rhythms, while therapy zones can be adjusted according to the patient’s documented arrhythmia. Changes should be made by an experienced electrophysiology or device team, with consideration of the indication for implantation, ventricular function, previous therapies and risk of rapid haemodynamic deterioration.

Treating the patient’s rhythm and substrate

Programming cannot replace treatment of recurrent atrial or ventricular arrhythmia. Rate control, rhythm control, correction of electrolyte disturbance, management of heart failure and review of stimulant or pro-arrhythmic medicines may all reduce episodes. Antiarrhythmic therapy can be useful in selected patients, but renal function, structural heart disease, QT interval, drug interactions and adverse effects must guide prescribing.

Catheter ablation may be appropriate for atrial fibrillation, atrial flutter or other supraventricular tachycardias that repeatedly trigger ICD therapy. It can also be considered for recurrent ventricular tachycardia in suitable patients with cardiomyopathy or scar. The underlying phenotype should be investigated carefully; resources on arrhythmogenic left ventricular cardiomyopathy illustrate why apparently similar ventricular arrhythmias may arise from different inherited or acquired substrates.

Australian practice also requires attention to practical medication access. Prescribers may need to consider Therapeutic Goods Administration approvals, Pharmaceutical Benefits Scheme restrictions and the availability of specialist follow-up when selecting antiarrhythmic treatment. In regional areas, a shared plan between the tertiary electrophysiologist, local cardiologist and primary care clinician helps prevent medication changes or abnormal blood tests from being missed.

Remote monitoring and lead surveillance

Remote device monitoring can identify arrhythmia episodes, lead noise, impedance changes, battery concerns and repeated therapies before a routine clinic appointment. It is especially valuable for patients who travel long distances from areas such as the Northern Territory, Far North Queensland or rural Western Australia. Connectivity is not universal, however, and patients may need help with the home transmitter, mobile coverage, consent processes and understanding which alerts require action.

Follow-up should include a reliable escalation pathway. An alert indicating lead failure or repeated inappropriate therapy needs clinical review, not simply acknowledgement in an electronic portal. Device clinics should document who checks alerts, how rapidly they are reviewed and how patients are contacted. This is important in both public hospitals and private cardiology practices, where staffing and vendor support can differ.

Patients should also know how to reduce avoidable interference and respond to symptoms. Household appliances used normally are generally safe, but powerful magnets, industrial equipment and certain medical procedures require specific advice. A magnet placed over an ICD can suspend tachycardia therapy temporarily; it should never be used at home as a substitute for medical assessment. Any such intervention requires a documented plan and prompt specialist review.

A coordinated approach to prevention

The most effective prevention programme combines accurate diagnosis, individualised programming, treatment of the provoking rhythm and dependable follow-up. Before discharge after implantation or a programming change, the patient should understand the purpose of each therapy zone, what a shock may feel like, whom to call and when to attend an emergency department. Family members can be included, particularly when syncope or repeated shocks is a concern.

At review, clinicians should assess psychological effects as well as electrical data. Fear of another shock may lead to avoidance of exercise, sleep disruption, low mood or reluctance to leave home. Referral to cardiac rehabilitation, counselling or a psychologist familiar with ICDs can support recovery. Exercise advice should reflect the underlying cardiomyopathy, ventricular function and arrhythmia history rather than the presence of the device alone.

Atrial fibrillation management may also intersect with anticoagulation decisions, especially in chronic kidney disease. The principles discussed in DOAC dosing and kidney disease are relevant when renal function changes or medicines are reviewed. Preventing stroke, reducing rapid atrial rhythms and avoiding medication toxicity all contribute to fewer emergency presentations, even though anticoagulation itself does not prevent an ICD shock.

Clinicians, device nurses and patients can reduce inappropriate shocks by treating every episode as useful diagnostic information. Review the electrograms, confirm the mechanism, check the lead system, adjust detection and discrimination settings, and address the arrhythmia or substrate driving the event. Journal of Arrhythmia provides open-access research and clinical perspectives that can support this work across Australian electrophysiology services. Explore its device and arrhythmia resources, and apply evidence-based review at the next ICD interrogation.